Skip to main content

Table 6 Effect of FVBM extract, F18 bioactive compound and atorvastatin on plasma triglycerides, total cholesterol and non-HDL-cholesterol in Triton WR-1339 induced hyperlipidemic rats after 18 hours of treatment

From: Bioactivity guided fractionation and hypolipidemic property of a novel HMG-CoA reductase inhibitor from Ficus virens Ait

Group Triglycerides Total cholesterol Non-HDL-cholesterol
NC 60.45 ± 1.22* 75.86 ± 1.32 47.5 ± 1.17
HLC 240.74 ± 3.36* 361.92 ± 4.86 328.38 ± 3.6
(+298.24%)a (+377.08%)a (+591.32%)a
FVT-1 95.47 ± 2.69* 126.17 ± 2.8 100.24 ± 2.5
(−60.34%)a (−65.13%)a (−69.47%)a
FVT-2 65.42 ± 1.17* 84.25 ± 1.25 53.3 ± 1.19
(−72.82%)a (−76.79%)a (−83.76%)a
CT 62.7 ± 1.48* 84.5 ± 2.25 55.8 ± 1.12
(−73.95%)a (−76.65%)a (−83.00%)a
AT 58.6 ± 1.15* 78.23 ± 1.25 49.6 ± 1.18
(−75.65%)a (−78.38%)a (−81.85%)a
  1. For the calculation of non-HDL-C, data is taken from Tables 5 and 6.
  2. *Values are mean (mg/dl) ± SD from plasma of 5 rats in each group.
  3. NC, normal control; HLC, triton induced hyperlipidemic control; FVT-1, fed 50 mg FVBM extract/ rat; FVT-2, fed 100 mg FVBM extract/ rat; CT, fed 1 mg F18 bioactive compound/ rat and AT, given 1 mg atorvastatin/rat once.
  4. Significantly different from NC at ap < 0.001.
  5. Significantly different from HLC at ap < 0.001.